Oral cholera vaccine coverage evaluation survey: Forcibly Displaced Myanmar Nationals and host community in Cox's Bazar, Bangladesh.
Bangladesh
Forcibly Displaced Myanmar Nationals
cholera
host community
oral cholera vaccine
refugee camps
vaccination
vaccine coverage
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
01
2023
accepted:
31
05
2023
medline:
24
7
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
epublish
Résumé
Cholera remains a significant public health concern in many parts of the world, particularly in areas with poor sanitation and hygiene. Bangladesh and other impoverished nations have been severely affected by cholera outbreaks, especially in areas with a high population density. In order to mitigate the spread of cholera, oral cholera vaccines (OCVs) are recommended as a prophylactic measure. In May 2018, 775,666 of the Forcibly Displaced Myanmar Nationals (FDMN) in the registered and makeshift camps and 103,605 of the residents in the host community received two doses of OCV Shanchol In August 2018, we enrolled 4,240 respondents for this study following the "World Health Organization (WHO) Vaccination Coverage Cluster Surveys: Reference Manual (2018)." The coverage survey was conducted with three strata of the population: the host community from the Teknaf Upazila, the registered camp, and the makeshift camp from the Ukhia Upazila. We collected information regarding OCV coverage, demographic characteristics, and knowledge and behaviors of people toward the vaccine. The data were analyzed using descriptive statistics. According to our study, the overall OCV coverage was 85%, with 68% in the host community, 91% in the registered camp, and 98% in the makeshift camp. The lower coverage in the host community was due to residents unaware of the vaccination campaign, the unavailability of vaccines, and unaware where to go for vaccination. Our findings demonstrate that the OCV campaign in the FDMN camps was successful, reaching over 90% coverage, while coverage in the host community was much lower. In order to make sure that OCV vaccination efforts are reaching the target population and having the desired impact, our study emphasizes the need to inform the target population of when and where to get vaccinated.
Identifiants
pubmed: 37475769
doi: 10.3389/fpubh.2023.1147563
pmc: PMC10354286
doi:
Substances chimiques
Cholera Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1147563Informations de copyright
Copyright © 2023 Qayum, Billah, Sarker, Alamgir, Nurunnahar, Khan, Salim Uzzaman, Henderson, Shirin and Flora.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Vaccine. 2013 Dec 9;31(51):6058-64
pubmed: 24161413
Lancet. 2018 May 12;391(10133):1877-1879
pubmed: 29781432
PLoS One. 2013;8(1):e54395
pubmed: 23349875
Vaccine. 2016 Jul 19;34(33):3823-7
pubmed: 27265459
Hum Vaccin Immunother. 2019;15(12):2882-2886
pubmed: 31441679
Emerg Infect Dis. 2017 Jan;23(1):38-45
pubmed: 27983502
Bull World Health Organ. 2012 Mar 1;90(3):209-218A
pubmed: 22461716
Emerg Infect Dis. 2015 Jun;21(6):984-91
pubmed: 25988350
Vaccine. 2020 Feb 29;38 Suppl 1:A132-A140
pubmed: 31519444
MMWR Morb Mortal Wkly Rep. 2018 May 11;67(18):533-535
pubmed: 29746454
Vaccine. 2007 Jan 4;25(2):231-8
pubmed: 16996172
PLoS One. 2018 Oct 3;13(10):e0198592
pubmed: 30281604
PLoS Negl Trop Dis. 2015 Jun 04;9(6):e0003832
pubmed: 26043000
Lancet. 2022 Apr 9;399(10333):1429-1440
pubmed: 35397865